MAX and cancer: Although altering the binding of this transcription factor could lead to differential drug response in cancer cell lines through the downstream effect of CLOCK and ATF4, we note that MAX itself has been implicated in cancer drug resistance as a prior study used the factor to distinguish cancer subtypes that explained differential drug response (Heiser et al., 2012).